Goldman Sachs Group Inc Tricida, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.14 - $12.49 $12,834 - $1.15 Million	-91,675 Reduced 16.57%	461,569 $69,000
Q4 2022 Feb 13, 2023	SELL	$0.14 - $12.49 $12,834 - $1.15 Million	-91,675 Reduced 16.57%	461,569 $69,000
Q3 2022 May 14, 2024	BUY	$8.51 - $13.6 $3.91 Million - $6.25 Million	459,840 Added 492.31%	553,244 $5.8 Million
Q3 2022 Nov 10, 2022	BUY	$8.51 - $13.6 $3.91 Million - $6.25 Million	459,840 Added 492.31%	553,244 $5.8 Million
Q2 2022 May 14, 2024	BUY	$7.31 - $11.85 $682,783 - $1.11 Million	93,404 New	93,404 $904,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $438,680 - $711,130	-60,011 Reduced 39.12%	93,404 $904,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $657,582 - $951,034	89,467 Added 139.91%	153,415 $1.26 Million
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $46,831 - $106,852	-11,177 Reduced 14.88%	63,948 $611,000
Q3 2021 Nov 10, 2021	BUY	$3.56 - $4.64 $267,445 - $348,580	75,125 New	75,125 $349,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.